CA2116138A1 - Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients - Google Patents
Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipientsInfo
- Publication number
- CA2116138A1 CA2116138A1 CA002116138A CA2116138A CA2116138A1 CA 2116138 A1 CA2116138 A1 CA 2116138A1 CA 002116138 A CA002116138 A CA 002116138A CA 2116138 A CA2116138 A CA 2116138A CA 2116138 A1 CA2116138 A1 CA 2116138A1
- Authority
- CA
- Canada
- Prior art keywords
- xenograft rejection
- compositions
- methods
- recipient
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 230000000250 revascularization Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Abstract
Antibody-mediated xenograft rejection is attenuated by (i) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's cieculation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74952991A | 1991-08-23 | 1991-08-23 | |
US07/749,529 | 1991-08-23 | ||
PCT/US1992/007071 WO1993003735A1 (en) | 1991-08-23 | 1992-08-21 | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2116138A1 true CA2116138A1 (en) | 1993-03-04 |
CA2116138C CA2116138C (en) | 2006-04-04 |
Family
ID=36143210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002116138A Expired - Fee Related CA2116138C (en) | 1991-08-23 | 1992-08-21 | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2116138C (en) |
-
1992
- 1992-08-21 CA CA002116138A patent/CA2116138C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2116138C (en) | 2006-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0661980A4 (en) | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients. | |
AU679437B2 (en) | Induced tolerance to xenografts | |
HK1102293A1 (en) | Graft rejection suppressors | |
Greenstein et al. | The use of tolerance for transplantation across xenogeneic barriers | |
EP1003552A4 (en) | LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION | |
EP0700297A4 (en) | Surrogate tolerogenesis for the development of tolerance to xenografts | |
AU1716297A (en) | Patient-specific immunoadsorbers for the extracorporeal apheresis and methods for their preparation | |
Teranishi et al. | Depletion of anti-gal antibodies in baboons by intravenous therapy with bovine serum albumin conjugated to gal oligosaccharides | |
SOARES et al. | IN VIVO DEPLETION OF XENOREACTIVE NATURAL ANTIBODIES WITH AN ANTI-μ MONOCLONAL ANTIBODY1, 2 | |
Rydberg et al. | Studies on the removal of anti‐pig xenoantibodies in the human by plasmapheresis/immunoadsorption | |
CA2116138A1 (en) | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients | |
Shaw et al. | Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature | |
CA2157500A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation | |
WO2004052305A3 (en) | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease | |
Ross et al. | Parathyroid transplantation: fate of a long-term allograft in man | |
Starzl et al. | Clinical xenotransplantation | |
HK1021318A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation | |
US20020168371A1 (en) | Process for reducing antibody response against xenografts | |
Guttmann et al. | RENAL TRANSPLANTATION IN THE INBRED RAT: XII. A Mechanism of Long-Term Survival of Allografts After Antithymocyte Immunoglobulin Treatment: 1, 2 | |
US5736136A (en) | Immunoglobulin infusion in xenotransplantation | |
Kanai et al. | Delayed hyperacute xenograft rejection in porcine to canine fetal liver transplantation | |
Friend | Rejection reactions to different organ transplants | |
Bustos et al. | The pathology of cardiac xenografts | |
Nikaein et al. | Correlation of HLA-class II genotyping with MLC and unrelated bone marrow transplant outcome | |
Sridhar et al. | Flowcytometric crossmatching in renal transplantation: Experience with quadruple immunosuppression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |